Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how

Drug Discovery Today

Volumn 19, Issue 8, 2014, Pages 1131-1136

  Hornberg, Jorrit J ^a   Laursen, Morten ^a   Brenden, Nina ^a   Persson, Mikael ^a   Thougaard, Annemette V ^a   Toft, Dorthe B ^a   Mow, Tomas ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; HUMAN; PHYSICAL CHEMISTRY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TOXICOLOGY; ADVERSE DRUG REACTION; ANIMAL; DRUG DESIGN; DRUG SCREENING; PROCEDURES; SAFETY;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; SAFETY;

EID: 84906317424     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.12.008     Document Type: Review

References (28)

1. K.I. Kaitin, and J.A. Dimasi Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009 Clin. Pharmacol. Ther. 89 2011 183 188
2. S. Morgan et al. The cost of drug development: a systematic review Health Policy 100 2011 4 17
3. S.M. Paul et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
4. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
5. J. Arrowsmith Trial watch: phase II failures: 2008-2010 Nat. Rev. Drug Discov. 10 2011 328 329
6. J. Arrowsmith Trial watch: phase III and submission failures: 2007-2010 Nat. Rev. Drug Discov. 10 2011 87
7. D.S. Budnitz et al. National surveillance of emergency department visits for outpatient adverse drug events JAMA 296 2006 1858 1866
8. J. Lazarou et al. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1998 1200 1205
9. J.A. Kramer et al. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates Nat. Rev. Drug Discov. 6 2007 636 649
10. V.G. Sasseville et al. Testing paradigm for prediction of development-limiting barriers and human drug toxicity Chem. Biol. Interact. 150 2004 9 25
11. C.E. Thomas, and Y. Will The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery Expert Opin. Drug Discov. 7 2012 109 122
12. P. Ma, and R. Zemmel Value of novelty? Nat. Rev. Drug Discov. 1 2002 571 572
13. T.L. Wallace et al. Drug targets for cognitive enhancement in neuropsychiatric disorders Pharmacol. Biochem. Behav. 99 2011 130 145
14. E.H.F. Wong et al. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective Int. J. Neuropsychopharmacol. 13 2010 1269 1284
15. J.J. Hornberg Simple drugs do not cure complex diseases: the need for multi-targeted drugs in designing multi-target drugs J.R. Morphy, J.C. Harris, Designing Multi-target Drugs 2012 The Royal Society of Chemistry 1 13
16. S. Hoelder et al. Discovery of small molecule cancer drugs: successes, challenges and opportunities Mol. Oncol. 6 2012 155 176
17. I. Manousaridis et al. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management J. Eur. Acad. Dermatol. Venereol. 27 2012 11 18
18. L. Peuvrel et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors Support. Care Cancer 20 2012 909 921
19. N.A. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 24 2011 1420 1456
20. T.T. Wager et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 1 2010 420 434
21. P.Y. Muller, and M.N. Milton The determination and interpretation of the therapeutic index in drug development Nat. Rev. Drug Discov. 11 2012 751 761
22. M. Fung et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999 Drug Inf. J. 35 2001 293 317
23. J.L. Stevens, and T.K. Baker The future of drug safety testing: expanding the view and narrowing the focus Drug Discov. Today. 14 2009 162 167
24. S.C. Gad Postmarketing safety evaluation: monitoring, assessing, and reporting of adverse drug responses Pharmaceutical Sciences Encyclopedia 2010 John Wiley & Sons
25. H. Olson et al. Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 32 2000 56 67
26. J.S. MacDonald, and R.T. Robertson Toxicity testing in the 21st century: a view from the pharmaceutical industry Toxicol. Sci. 110 2009 40 46
27. W.S. Redfern et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle Toxicologist 114 2010 1081
28. J.J. Hornberg et al. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies Drug Discov. Today 2013 http://dx.doi.org/10.1016/j.drudis.2013.12.009